


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

1. (Previously Amended) A compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a monocyclic heteroaromatic ring selected from the group consisting of thiophene, furan, pyrrole, pyridine, pyrimidine, pyridazine, and pyrazine;

R¹ is H, OH, OC₁₋₃alkyl, C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH, or OC₁₋₃alkyl;

R² is H, halogen, C₁₋₃alkyl, CONR⁵R⁶, S(=O)_mC₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH, or OC₁₋₃alkyl; with the proviso that if Aryl is thiophene, then R² ≠ H or halo, and R¹ ≠ OH

R³, R⁴ are independently H, C₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁵, R⁶ are independently H, C₁₋₃alkyl, or C₂₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, where R⁵ and R⁶ optionally can be joined together to form a pyrrolidine or piperidine ring which can be either unsubstituted or substituted optionally with C₁₋₃alkyl, C₂₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;


R⁷, R⁸ are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ³-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl, or substituted on nitrogen with C₁₋₄alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl;

n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt or solvate thereof.

2. (Currently Amended) A compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring selected from the group consisting of thiophene, furan, pyrrole, pyridine, pyrimidine, pyridazine, and pyrazine;

R¹ is H, C₁₋₅alkyl, C₃₋₅alkenyl, an aromatic ring selected from the group consisting of phenyl, thienyl, pyridyl, and imidazolyl which is either unsubstituted or substituted optionally with OH, OC₁₋₃alkyl, S(=O)_mC₁₋₃alkyl, halogen, or CF₃; or C₂₋₅alkyl substituted optionally with OH, OC₁₋₃alkyl, S(=O)_mC₁₋₃alkyl or an aromatic ring selected from the group consisting of phenyl, thienyl, pyridyl, and imidazolyl, which is either unsubstituted or substituted optionally with OH, OC₁₋₃alkyl, S(=O)_mC₁₋₃alkyl, halogen, CF₃, S(=O)₂NR⁵R⁶; or C₃₋₅alkenyl substituted optionally with OH, OC₁₋₃alkyl, or S(=O)_mC₁₋₃alkyl;

R² is H, halogen, C₁₋₃alkyl, S(=O)_mC₁₋₃alkyl, S(=O)₂NR⁵R⁶, or C₁₋₃alkyl substituted optionally with OH, or OC₁₋₃alkyl;

R³ & R⁴ are independently H, C₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁵, R⁶ are independently H, C₁₋₃alkyl, or C₂₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, where R⁵ and R⁶ optionally can be joined together to form a pyrrolidine or piperidine ring which can be either unsubstituted or substituted optionally with C₁₋₃alkyl, C₂₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁷, R⁸ are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ³-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl, or substituted on nitrogen with C₁₋₄alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl;

n is 2 to 4;


m is 0, 1 or 2

or a pharmaceutically acceptable salt or solvate thereof.

3. (Withdrawn)

4. (Withdrawn)

5. (Currently Amended) A method for lowering IOP which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring selected from the group consisting of thiophene, furan, pyrrole, pyridine, pyrimidine, pyridazine, and pyrazine;

R¹ is H, OH, OC₁₋₃alkyl, C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH, or OC₁₋₃alkyl;

R² is H, halogen, C₁₋₃alkyl, CONR⁵R⁶, S(=O)_mC₁₋₃alkyl⁶, or C₁₋₃alkyl substituted optionally with OH, or OC₁₋₃alkyl;

R³, R⁴ are independently H, C₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁵, R⁶ are independently H, C₁₋₃alkyl, or C₂₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, where R⁵ and R⁶ optionally can be joined together to form a pyrrolidine or piperidine ring which can be either unsubstituted or substituted optionally with C₁₋₃alkyl, C₂₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;


R⁷, R⁸ are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ³-piperidine, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl, or substituted on nitrogen with C₁₋₄alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl;

n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt or solvate thereof.

6. (Currently Amended) A method for lowering IOP which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring selected from the group consisting of thiophene, furan, pyrrole, pyridine, pyrimidine, pyridazine, and pyrazine;

R¹ is H, C₁₋₃alkyl, C₃₋₅alkenyl, an aromatic ring selected from the group consisting of phenyl, thienyl, pyridyl, and imidazolyl, which is either unsubstituted or substituted optionally with OH, OC₁₋₃alkyl, S(=O)_mC₁₋₃alkyl, halogen, CF₃, or S(=O)₂NR⁵R⁶; or C₂₋₅alkyl substituted optionally with OH, OC₁₋₃alkyl, S(=O)_mC₁₋₃alkyl or an aromatic ring selected from the group consisting of phenyl, thienyl, pyridyl, and imidazolyl, which is either unsubstituted or substituted optionally with OH, OC₁₋₃alkyl, S(=O)_mC₁₋₃alkyl, halogen, CF₃, S(=O)₂NR⁵R⁶; or C₃₋₅alkenyl substituted optionally with OH, OC₁₋₃alkyl, or S(=O)_mC₁₋₃alkyl;

R² is H, halogen, C₁₋₃alkyl, S(=O)_mC₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH, or OC₁₋₃alkyl;

R³ & R⁴ are independently H, C₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁵, R⁶ are independently H, C₁₋₃alkyl, or C₂₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, where R⁵ and R⁶ optionally can be joined together to form a pyrrolidine or piperidine ring which can be either unsubstituted or substituted optionally with C₁₋₃alkyl, C₂₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁷, R⁸ are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ³-piperidine, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C₁₋

alkyl, or C₁₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl, or substituted on nitrogen with C₁₋₄alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl;

n is 2 to 4;


m is 0, 1 or 2

or a pharmaceutically acceptable salt or solvate thereof.

7. (Withdrawn)

8. (Withdrawn)

9. (Currently Amended) A method for improving blood flow to the optic nerve head and the retina which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring selected from the group consisting of thiophene, furan, pyrrole, pyridine, pyrimidine, pyridazine, and pyrazine;

R¹ is H, OH, OC₁₋₃alkyl, C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH, or OC₁₋₃alkyl;

R² is H, halogen, C₁₋₃alkyl, CONR⁵R⁶, S(=O)_mC₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH, or OC₁₋₃alkyl;

R³, R⁴ are independently H, C₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁵, R⁶ are independently H, C₁₋₃alkyl, or C₂₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, where R⁵ and R⁶ optionally can be joined together to form pyrrolidine or piperidine ring which can be either unsubstituted or substituted optionally with C₁₋₃alkyl, C₂₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁷, R⁸ are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ³-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or


substituted on carbon with one or more substituents optionally selected from C_{1-3} alkyl, or C_{1-3} alkyl substituted optionally with OH, OC_{1-3} alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3 , OC_{1-3} alkyl, or C_{1-3} alkyl, or substituted on nitrogen with C_{1-4} alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3 , OC_{1-3} alkyl, or C_{1-3} alkyl;

n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt or solvate thereof.

10. (Currently Amended) A method for improving blood flow to the optic nerve head and the retina which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring selected from the group consisting of thiophene, furan, pyrrole, pyridine, pyrimidine, pyridazine, and pyrazine;

R^1 is H, C_{1-3} alkyl, C_{3-5} alkenyl, an aromatic ring selected from the group consisting of phenyl, thienyl, pyridyl, and imidazolyl, which is either unsubstituted or substituted optionally with OH, OC_{1-3} alkyl, $S(=O)_mC_{1-3}$ alkyl, halogen, CF_3 , or $S(=O)_2NR^5R^6$; or C_{2-5} alkyl substituted optionally with OH, OC_{1-3} alkyl, $S(=O)_mC_{1-3}$ alkyl or an aromatic ring selected from the group consisting of phenyl, thienyl, pyridyl, and imidazolyl, which is either unsubstituted or substituted optionally with OH, OC_{1-3} alkyl, $S(=O)_mC_{1-3}$ alkyl, halogen, CF_3 , $S(=O)_2NR^5R^6$; or C_{3-5} alkenyl substituted optionally with OH, OC_{1-3} alkyl, or $S(=O)_mC_{1-3}$ alkyl;

R^2 is H, halogen, C_{1-3} alkyl, $S(=O)_mC_{1-3}$ alkyl, or C_{1-3} alkyl substituted optionally with OH, or OC_{1-3} alkyl;

R^3 & R^4 are independently H, C_{1-3} alkyl, or C_{1-3} alkyl substituted optionally with OH or OC_{1-3} alkyl;

R^5 , R^6 are independently H, C_{1-3} alkyl, or C_{2-3} alkyl substituted optionally with OH, OC_{1-3} alkyl, where R^5 and R^6 optionally can be joined to form a pyrrolidine or piperidine ring which can be either unsubstituted or substituted optionally with C_{1-3} alkyl;

₃alkyl, C₂₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁷, R⁸ are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ³-piperidine, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl, or substituted on nitrogen with C₁₋₄alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl;

n is 2 to 4;


m is 0, 1 or 2

or a pharmaceutically acceptable salt or solvate thereof.

11. (Withdrawn)

12. (Withdrawn)

13. (Currently Amended) A method for treating retinal diseases selected from the group consisting of glaucoma, age related macular degeneration (ARMD), optic neuritis, ischemic disorders, diabetic retinopathy, and retinal edema which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring selected from the group consisting of thiophene, furan, pyrrole, pyridine, pyrimidine, pyridazine, and pyrazine;

R¹ is H, OH, OC₁₋₃alkyl, C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH, or OC₁₋₃alkyl;

R² is H, halogen, C₁₋₃alkyl, CONR⁵R⁶, S(=O)_mC₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH, or OC₁₋₃alkyl;

R³, R⁴ are independently H, C₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁵, R⁶ are independently H, C₁₋₃alkyl, or C₂₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl,

where R^5 and R^6 optionally can be joined together to form a pyrrolidine or piperidine ring which can be either unsubstituted or substituted optionally with C_{1-3} alkyl, C_{2-3} alkyl substituted optionally with OH or OC_{1-3} alkyl;


R^7 , R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3 -piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3} alkyl, or C_{1-3} alkyl substituted optionally with OH, OC_{1-3} alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3 , OC_{1-3} alkyl, or C_{1-3} alkyl, or substituted on nitrogen with C_{1-4} alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3 , OC_{1-3} alkyl, or C_{1-3} alkyl;

n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt or solvate thereof.

14. (Currently Amended) A method for treating retinal diseases selected from the group consisting of glaucoma, age related macular degeneration (ARMD), optic neuritis, ischemic disorders, diabetic retinopathy, and retinal edema which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring selected from the group consisting of thiophene, furan, pyrrole, pyridine, pyrimidine, pyridazine, and pyrazine:

R^1 is H, C_{1-5} alkyl, C_{3-5} alkenyl, an aromatic ring selected from the group ~~consisting~~ consisting of phenyl, thienyl, pyridyl, and imidazolyl, which is either unsubstituted or substituted optionally with OH, OC_{1-3} alkyl, $S(=O)_mC_{1-3}$ alkyl, halogen, CF_3 , or $S(=O)_2NR^5R^6$; or C_{2-5} alkyl substituted optionally with OH, OC_{1-3} alkyl, $S(=O)_mC_{1-3}$ alkyl or an aromatic ring selected from the group consisting of phenyl, thienyl, pyridyl, and imidazolyl which is either unsubstituted or substituted optionally with OH, OC_{1-3} alkyl, $S(=O)_mC_{1-3}$ alkyl, halogen, CF_3 , $S(=O)_2NR^5R^6$; or C_{3-5} alkenyl substituted optionally with OH, OC_{1-3} alkyl, or $S(=O)_mC_{1-3}$ alkyl;

R² is H, halogen, C₁₋₃alkyl, S(=O)_mC₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH, or OC₁₋₃alkyl;

R³ & R⁴ are independently H, C₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁵, R⁶ are independently H, C₁₋₃alkyl, or C₂₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, where R⁵ and R⁶ optionally can be joined together to form a pyrrolidine or piperidine ring which can be either unsubstituted or substituted optionally with C₁₋₃alkyl, C₂₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁷, R⁸ are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ³-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl, or substituted on nitrogen with C₁₋₄alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl;

n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt or solvate thereof.

15. (Withdrawn)

16. (Withdrawn)

17. (Cancelled)

18. (Cancelled)

19. (Withdrawn)

20. (Withdrawn)


21. (Cancelled)

22. (Cancelled)

23. (Withdrawn)

24. (Withdrawn)
25. (Cancelled)
26. (Cancelled)
27. (Withdrawn)
28. (Withdrawn)
29. (Withdrawn)
30. (Withdrawn)
31. (Withdrawn)
32. (Withdrawn)
33. (Withdrawn)
34. (Cancelled)
35. (Withdrawn)
36. (Withdrawn)
37. (Withdrawn)
38. (Withdrawn)

39. (Currently Amended) A method for treating persons suffering from a sleeping disorder, depression, schizophrenia, anxiety, circadian rhythm disorders, and centrally and peripherally mediated hypertension, which comprises, administering a composition comprising a pharmaceutically effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring selected from the group consisting of thiophene, furan, pyrrole, pyridine, pyrimidine, pyridazine, and pyrazine;

R^1 is H, OH, $OC_{1-3}alkyl$, $C_{1-3}alkyl$, $C_{1-3}alkyl$ substituted optionally with OH, or $OC_{1-3}alkyl$;

R^2 is H, halogen, $C_{1-3}alkyl$, $CONR^5R^6$, $S(=O)_mC_{1-3}alkyl$, $S(=O)_2NR^5R^6$, $C_{1-3}alkyl$ substituted optionally with OH, or $OC_{1-3}alkyl$;

R^3 , R^4 are independently H, $C_{1-3}alkyl$, or $C_{1-3}alkyl$ substituted optionally with OH or $OC_{1-3}alkyl$;

R^5 , R^6 are independently H, $C_{1-3}alkyl$, or $C_{2-3}alkyl$ substituted optionally with OH, $OC_{1-3}alkyl$, where R^5 and R^6 optionally can be joined together to form a pyrrolidine or piperidine ring which can be either unsubstituted or substituted optionally with $C_{1-3}alkyl$, $C_{2-3}alkyl$ substituted optionally with OH or $OC_{1-3}alkyl$;

R^7 , R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3 -piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from $C_{1-3}alkyl$, or $C_{1-3}alkyl$ substituted optionally with OH, $OC_{1-3}alkyl$, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3 , $OC_{1-3}alkyl$, or $C_{1-3}alkyl$, or substituted on nitrogen with $C_{1-4}alkoxy$ or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3 , $OC_{1-3}alkyl$, or $C_{1-3}alkyl$;


n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt or solvate thereof.

40. (Currently Amended) A method for treating persons suffering from a sleeping

disorder, depression, schizophrenia, anxiety, obsessive compulsive disorder, circadian rhythm disorders, and centrally and peripherally mediated hypertension which comprises, administering a composition comprising a pharmaceutically effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring selected from the group consisting of thiophene, furan, pyrrole, pyridine, pyrimidine, pyridazine, and pyrazine;

R¹ is H, C₁₋₃alkyl, C₃₋₅alkenyl, an aromatic ring selected from the group consisting of phenyl, thienyl, pyridyl, and imidazolyl, which is either unsubstituted or substituted optionally with OH, OC₁₋₃alkyl, S(=O)_mC₁₋₃alkyl, halogen, CF₃, or S(=O)₂NR⁵R⁶; or C₂₋₅alkyl substituted optionally with OH, OC₁₋₃alkyl, S(=O)_mC₁₋₃alkyl or an aromatic ring selected from the group consisting of phenyl, thienyl, pyridyl, and imidazolyl which is either unsubstituted or substituted optionally with OH, OC₁₋₃alkyl, S(=O)_mC₁₋₃alkyl, halogen, CF₃, S(=O)₂NR⁵R⁶; or C₃₋₅alkenyl substituted optionally with OH, OC₁₋₃alkyl, or S(=O)_mC₁₋₃alkyl;

R² is H, halogen, C₁₋₃alkyl, S(=O)_mC₁₋₃alkyl, S(=O)₂NR⁵R⁶, or C₁₋₃alkyl substituted optionally with OH, or OC₁₋₃alkyl;

R³ & R⁴ are independently H, C₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁵, R⁶ are independently H, C₁₋₃alkyl, or C₂₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, where R⁵ and R⁶ optionally can be joined together to form a pyrrolidine or piperidine and which can be either unsubstituted or substituted optionally with C₁₋₃alkyl, C₂₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁷, R⁸ are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ³-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl, or substituted on nitrogen with C₁₋₄alkoxy or phenyl which can be

unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl;

n is 2 to 4;


m is 0, 1 or 2

or a pharmaceutically acceptable salt or solvate thereof.

41. (Withdrawn)

42. (Withdrawn)

43. (Previously Amended) A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a monocyclic heteroaromatic ring selected from the group consisting of

thiophene, furan, pyrrole, pyridine, pyrimidine, pyridazine, and pyrazine;

R¹ is H, OH, OC₁₋₃alkyl, C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH, or OC₁₋₃alkyl;

R² is H, halogen, C₁₋₃alkyl, CONR⁵R⁶, S(=O)_mC₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH, or OC₁₋₃alkyl; with the proviso that if Aryl is thiophene, then R² ≠ H or halo, and R¹ ≠ OH

R³, R⁴ are independently H, C₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁵, R⁶ are independently H, C₁₋₃alkyl, or C₂₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, where R⁵ and R⁶ optionally can be joined together to form a pyrrolidine or piperidine ring which can be either unsubstituted or substituted optionally with C₁₋₃alkyl, C₂₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁷, R⁸ are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ³-piperidine, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋


3alkyl, or substituted on nitrogen with C₁₋₄alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl;

n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt or solvate thereof in a pharmaceutically acceptable carrier.

44. (Previously Amended) A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a monocyclic heteroaromatic ring selected from the group consisting of thiophene, furan, pyrrole, pyridine, pyrimidine, pyridazine, and pyrazine;

R¹ is H, C₁₋₅alkyl, C₃₋₅alkenyl, an aromatic ring selected from the group consisting of phenyl, thienyl, pyridyl, and imidazolyl which is either unsubstituted or substituted optionally with OH, OC₁₋₃alkyl, S(=O)_mC₁₋₃alkyl, halogen, or CF₃; or C₂₋₅alkyl substituted optionally with OH, OC₁₋₃alkyl, S(=O)_mC₁₋₃alkyl or an aromatic ring selected from the group consisting of phenyl, thienyl, pyridyl, and imidazolyl, which is either unsubstituted or substituted optionally with OH, OC₁₋₃alkyl, S(=O)_mC₁₋₃alkyl, halogen, CF₃, S(=O)₂NR⁵R⁶; or C₃₋₅alkenyl substituted optionally with OH, OC₁₋₃alkyl, or S(=O)_mC₁₋₃alkyl;

R² is H, halogen, C₁₋₃alkyl, S(=O)_mC₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH, or OC₁₋₃alkyl;

R³ & R⁴ are independently H, C₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁵, R⁶ are independently H, C₁₋₃alkyl, or C₂₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, where R⁵ and R⁶ optionally can be joined together to form a pyrrolidine or piperidine ring which can be either unsubstituted or substituted optionally with C₁₋₃alkyl, C₂₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁷, R⁸ are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ³-piperidine, piperazine, morpholine or thiomorpholine which can be unsubstituted

or substituted on carbon with one or more substituents optionally selected from C₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl, or substituted on nitrogen with C₁₋₄alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl;

n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt or solvate thereof in a pharmaceutically acceptable carrier.

45. (Withdrawn)

46. (Withdrawn)

47. (Original) The Compound of Claim 1 selected from the group consisting of:
6-Chloro-2-[4-[4-(2*H*-benzimidazo-2-oxo-1-yl)piperidin-1-yl]butyl]-2*H*-thieno[3,2-*e*]-1,2-thiazine 1,1-dioxide;
6-Chloro-2-[4-(4-phenylpiperazin-1-yl)butyl]-2*H*-thieno[3,2-*e*]-1,2-thiazine 1,1-dioxide;
6-Chloro-2-[4-[4-(2-fluorophenyl)piperazin-1-yl]butyl]-2*H*-thieno[3,2-*e*]-1,2-thiazine 1,1-dioxide;
6-Chloro-2-[3-[4-(3-trifluoromethylphenyl)piperazin-1-yl]propyl]-2*H*-thieno[3,2-*e*]-1,2-thiazine 1,1-dioxide;
6-Chloro-2-[3-[4-(2*H*-benzimidazol-2-oxo)piperidin-1-yl]propyl]-2*H*-thieno[3,2-*e*]-1,2-thiazine 1,1-dioxide.

48. (Withdrawn)

49. (Withdrawn)